Category

Archives

TAM Receptor

ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial

65 views | Jun 02 2019

Gorcea CM et al. showed that ASP2215 (gilteritinib) is a novel, dual FLT3/AXL inhibitor with promising early phase trial data (NCT02014558). [Read the Full Post]

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

46 views | Apr 24 2019

Pinato DJ et al. found that suppression of Axl-dependent signalling influences the transformed phenotype in HCC cells and contributes to adaptive resistance to sorafenib, providing a pre-clinical rationale for the development of Axl inhibitors as a measure to overcome sorafenib resistance. [Read the Full Post]

Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout

156 views | Nov 09 2018

Liu L et al. revealed that IL-37 limits runaway inflammation initiated by MSU crystal-induced immune responses, partly in a Mertk-dependent fashion. Thus, rhIL-37 has both preventive and therapeutic effects in gouty arthritis. [Read the Full Post]

Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells

696 views | Nov 04 2017

Lu Y et al. suggested that AXL can undergo sequential processing mediated by various proteases kept in a homeostatic balance. [Read the Full Post]

Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways

731 views | Aug 21 2017

Zhang L et al. showed that Fisetin effectively increased sensitivity of Erlotinib-resistant lung cancer cells to Erlotinib, possibly by inhibiting aberrant activation of MAPK and AKT signaling pathways resulted from AXL suppression. [Read the Full Post]

MET Inhibition in Clear Cell Renal Cell Carcinoma

0 views | Jul 01 2017

Xie Z et al. provided further preclinical rationale for dual MET/VEGFR2 inhibition in ccRCC. [Read the Full Post]

MET Inhibition in Clear Cell Renal Cell Carcinoma

1923 views | Dec 23 2016

Xie Z et al. provide further preclinical rationale for dual MET/VEGFR2 inhibition in ccRCC. [Read the Full Post]

The anti-inflammatory effect of IL-37-IL-1R8-IL-18Rα complex

2130 views | Mar 17 2015

Nold-Petry et al. identified the endogenous ligand-receptor complex IL-37-IL-1R8-IL-18Rα. [Read the Full Post]

AXL regulates cetuximab resistance in HNSCC and NSCLC

5403 views | Mar 13 2015

Brand et al. demonstrated that AXL-EGFR signaling positive feedback loop is one of the mechanism of developing cetuximab resistance. [Read the Full Post]

Two states of BRAFV600 mutant melanoma that related to MAPK inhibition resistance

5999 views | Dec 31 2014

Konieczkowski et al. revealed the mechanism of MAPK inhibition on BRAFV600 mutant melanomas. [Read the Full Post]